Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps

Bagnasco, Diego; Canevari, Rikki; Del Giacco, Stefano; Ferrucci, Silvia; Pigatto, Paolo; Castelnuovo, Paolo; Marseglia, Gian; Yalcin, Arzu; Pelaia, Girolamo; Canonica, Giorgio

doi:10.1016/j.waojou.2022.100721

Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps

Bagnasco D., Canevari R. F., Del Giacco S., Ferrucci S., Pigatto P., Castelnuovo P., ...Daha Fazla

World Allergy Organization Journal, cilt.15, sa.12, 2022 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Kısa Makale
Cilt numarası: 15 Sayı: 12
Basım Tarihi: 2022
Doi Numarası: 10.1016/j.waojou.2022.100721
Dergi Adı: World Allergy Organization Journal
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, Food Science & Technology Abstracts, Directory of Open Access Journals
Anahtar Kelimeler: Severe asthma, Omalizumab, Cancer, Anti IgE, Monoclonal antibodies
Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Omalizumab is a biological drug targeting circulating IgE, approved for use in allergic asthma, chronic spontaneous urticaria, and recently for chronic rhinosinusitis with nasal polyps, with good efficacy in all these settings. Some concerns about omalizumab safety have been raised as its use has been recently linked to potential increased cancer risk. Nevertheless, literature evidence does not support this statement, and clinical studies and evidence from real-world registries and surveillance analysis have consistently reported drug safety.